Pluristem Life Systems Retains Biologics Consulting Group To Pursue FDA Approval Of PLX-1

Haifa, Israel - Pluristem Life Systems, Inc., a cell therapy company dedicated to the commercialization of stem cell products, announces it has engaged Biologics Consulting Group, Inc. to assist in the Company's pursuit of FDA approval of PLX-1. Pluristem's PLX-1 will enable umbilical cord blood to become an alternative to bone marrow transplant, eliminating the current bone marrow transplant search and match process.

Zami Aberman, CEO of Pluristem, states, "Biologics Consulting Group will advise us on the most expeditious way to pursue FDA approval of PLX-1. Their well-conceived plan includes a detailed assessment of the most effective pathway to approval and then to market. We expect to immediately implement their strategy."

"We are pleased to have been chosen by Pluristem to assist in the development of a regulatory strategy specifically tailored to expedite timely review and approval of PLX-1 by the FDA," notes Dr. Andra E. Miller, Director, Cell and Gene Therapy, Biologics Consulting Group, Inc.

SOURCE: Pluristem Life Systems, Inc.